EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Chemotherapy–Surgery Interval Effects on Tumor Necrosis and Outcome in Children and Young Adults With Osteosarcoma

Rachel B Mersfelder iD, Cara Lwin, Shahid Malik, Thomas C Badgett, Stephen W Chenard, Akhil Rekulapelli, Bryan S Blette, Joshua M Lawrenz iD, Scott C Borinstein iD

Pediatric Blood & Cancer · 2025-03 · 72 (3)

DOI: 10.1002/pbc.31466 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric Blood & Cancer, online erschienen am 09.12.2024. Verfasst von Rachel B Mersfelder und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pediatric Hematology/Oncology, Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee, USA. Hauptthemen laut MEDLINE: Osteosarcoma, Bone Neoplasms, Neoadjuvant Therapy, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Clinical and Translational Science Award, NCATS NIH HHS, National Center for Advancing Translational Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objective Osteosarcoma treatment incorporates chemotherapy and surgery. Resection of the primary tumor usually occurs after induction chemotherapy. Occasionally, scheduling challenges and medical complications result in delay. The goal of this study is to determine if an increased interval between completion of neoadjuvant therapy and surgical resection correlates with decreased tumor necrosis and inferior outcomes in children and young adults with osteosarcoma. Design/Method We conducted a retrospective chart review of 121 patients age less than 40 years diagnosed with osteosarcoma treated at a single tertiary medical center between 2000 and 2022. Inclusion criteria included receipt of two cycles of neoadjuvant methotrexate, cisplatin, and doxorubicin. Association of the interval from completion of induction chemotherapy to resection with tumor necrosis (Spearman's correlation) and outcomes (multivariable Cox hazard regression) were analyzed.

Results

There was no significant correlation between interval length and tumor necrosis. However, patients with an interval greater than 16 days had lower 5‐year event‐free survival ( p = 0.019). Multivariable adjusted analysis of patients with initially localized disease revealed that each day increase in interval length corresponds with a 1.1 times greater hazard of having an event (95% CI: 1.0–1.2; p = 0.016).

Conclusion

Delays in local control were not associated with tumor necrosis. This is consistent with the hypothesis that tumor necrosis is a biologic marker of a tumor's sensitivity to chemotherapy and may not be affected by minor regimen aberrations. However, surgical delay from completion of induction chemotherapy may confer worse outcomes. Longer intervals generally confer worse outcomes in patients with initially localized disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OsteosarcomaBone NeoplasmsNeoadjuvant TherapyAntineoplastic Combined Chemotherapy ProtocolsHumansChildFemaleMaleAdolescentRetrospective StudiesYoung AdultNecrosisAdultChild, PreschoolSurvival RateFollow-Up StudiesMethotrexateDoxorubicinPrognosisCisplatin

Stichwörter der Autor:innen

cancerchemotherapyosteosarcomaoutcomespediatrics

Substanzen

MethotrexateDoxorubicinCisplatin

Autor:innen und Institutionen

  • Division of Pediatric Hematology/Oncology, Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
  • Department of Biostatistics, Vanderbilt University, Nashville, Tennessee, USA.
  • Division of Pediatric Hematology-Oncology, Department of Pediatrics, East Tennessee Children's Hospital, Knoxville, Tennessee, USA.
  • Division of Pediatric Hematology-Oncology, Kentucky Children's Hospital, Louisville, Kentucky, USA.
  • Department of Orthopedic Surgery, Vanderbilt University Medical Center, Nashville, Tennessee, USA.

ORCID-Profile: Rachel B Mersfelder, Joshua M Lawrenz, Scott C Borinstein

Förderung

  • Clinical and Translational Science Award
  • NCATS NIH HHS
  • National Center for Advancing Translational Sciences

Zitieren

APA

Mersfelder, R. B., Lwin, C., Malik, S., Badgett, T. C., Chenard, S. W., Rekulapelli, A., Blette, B. S., Lawrenz, J. M., & Borinstein, S. C. (2025). Chemotherapy–Surgery Interval Effects on Tumor Necrosis and Outcome in Children and Young Adults With Osteosarcoma. Pediatric Blood & Cancer, 72(3). https://doi.org/10.1002/pbc.31466

Vancouver

Mersfelder RB, Lwin C, Malik S, Badgett TC, Chenard SW, Rekulapelli A, et al. Chemotherapy–Surgery Interval Effects on Tumor Necrosis and Outcome in Children and Young Adults With Osteosarcoma. Pediatric Blood & Cancer. 2025;72(3). doi:10.1002/pbc.31466

BibTeX
@article{Mersfelder2025,
  author = {Mersfelder, Rachel B and Lwin, Cara and Malik, Shahid and Badgett, Thomas C and Chenard, Stephen W and Rekulapelli, Akhil and Blette, Bryan S and Lawrenz, Joshua M and Borinstein, Scott C},
  title = {Chemotherapy–Surgery Interval Effects on Tumor Necrosis and Outcome in Children and Young Adults With Osteosarcoma},
  journal = {Pediatric Blood & Cancer},
  year = {2025},
  volume = {72},
  number = {3},
  doi = {10.1002/pbc.31466}
}
Kostenlos starten →